首页|Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update

Biomarkers of Metabolic (Dysfunction)-associated Fatty Liver Disease: An Update

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
The prevalence of metabolic (dysfunction)-associated fatty liver disease (MAFLD) is rapidly increasing and affects up to two billion individuals globally, and this has also resulted in increased risks for cirrhosis, hepatocellular carcinoma, and liver transplants. In addition, it has also been linked to extrahepatic consequences, such as cardiovascular disease, diabetes, and various types of cancers. However, only a small proportion of patients with MAFLD develop these com-plications. Therefore, the identification of high-risk patients is paramount. Liver fibrosis is the major determinant in de-veloping these complications. Although, liver biopsy is still considered the gold standard for the assessment of patients with MAFLD. Because of its invasive nature, among many other limitations, the search for noninvasive biomarkers for MAFLD remains an area of intensive research. In this review, we provide an update on the current and future biomarkers of MAFLD, including a discussion of the associated genetics, epigenetics, microbiota, and metabolomics. We also touch on the next wave of multiomic-based biomarkers.

BiomarkersMetabolic (dysfunction)-associated fatty liver diseaseScores

Jawaher Alharthi、Mohammed Eslam

展开 >

Storr Liver Centre,Westmead Institute for Medical Research,Westmead Hospital and University of Sydney,Sydney,NSW,Australia

Department of Biotechnology,Faculty of Science,Taif University,Taif,Saudi Arabia

Robert W.Storr Bequest to the Syd-ney Medical Foundation,University of SydneyNational Health and Medical Research Council of Australia(NHMRC)program grantsNational Health and Medical Research Council of Australia(NHMRC)program grantsvarious pro-ject grantsvarious pro-ject grantsvarious pro-ject grantsvarious pro-ject grants

10532061149976110717811084222001692

2022

10.14218/JCTH.2021.00248

临床与转化肝病杂志(英文版)

临床与转化肝病杂志(英文版)

ISSN：
年,卷(期)：2022.10(1)
  • 1
  • 1